NCT02039674View on ClinicalTrials.gov

A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

February 21, 2014

Primary Completion Date

November 7, 2016

Study Completion Date

October 18, 2021

Conditions
Non-small Cell Lung Carcinoma
Interventions
BIOLOGICAL

Pembrolizumab

IV on Day 1 of each 3-week cycle prior to chemo/immunotherapy

DRUG

Paclitaxel

IV on Day 1 of each 3-week cycle for a maximum of 4 administrations

DRUG

Carboplatin

IV on Day 1 of each 3-week cycle for a maximum of 4 administrations

BIOLOGICAL

Bevacizumab

IV on Day 1 of each 3-week cycle

DRUG

Pemetrexed

IV on Day 1 of each 3-week cycle

BIOLOGICAL

Ipilimumab

IV on Day 1 of each 3-week cycle for a maximum of 4 administrations

DRUG

Erlotinib

Orally tablet once daily

DRUG

Gefitinib

Oral tablet once daily

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02039674 - A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | Biotech Hunter | Biotech Hunter